Short Communication

International Journal of Clinical Rheumatology

Influence of single nucleotide polymorphisms on the efficacy of platelet-rich plasma in the treatment of injuries

Ricard Pruna*

F.C. Barcelona Medical Head Services, FIFA Medical Center of Excellence, Barcelona, Spain

*Author for correspondence: ricard.pruna@fcbarcelona.cat

Single nucleotide polymorphisms in platelet-rich plasma

Tissue repair in musculoskeletal injuries is often a slow and sometimes incomplete process. Musculoskeletal injuries have a great impact on athletes' especially elite athletes – and a rapid recovery of full efficiency and return to competition is of primary importance. The search for a minimally invasive treatment of these injuries is of great importance, especially in the world of sports.

The use of growth factors is thought to be useful in clinical practice because it promotes rapid healing with a high-quality tissue and allows a nearly and safe return to unrestricted activity. Platelet-rich plasma (PRP) is a simple and minimally invasive way to obtain a natural concentration of autologous growth factors, including IGF, EGF, TGFb1, and FGF2.

PRP is currently being widely experimented in different fields of medicine due to its ability to help in the regeneration of tissue with low healing potential. Since PRP was first introduced as topical adjuvant therapy to treat chronicle ulcers in the late 1980s [1], its use has been extended to many fields of medicine, such as dermatology, ophthalmology [2], dentistry [3] and maxillofacial surgery [3]. Recently, PRP injections have emerged as a fashionable non-invasive treatment also in sports medicine [4], where they are used to treat acute or chronic tendinopathy [5-8] and muscle [9,10] and ligament [11,12] injuries, because PRP provides numerous growth factors needed to promote the healing process and an analysis of the literature reveals a lack of solid evidence supporting the use of PRP [13].

The analysis of the literature shows promising preclinical results but contradictory clinical findings in individual response to treatment in sports injuries.

These contradictions could be due to inter individual differences in the presence of single nucleotide polymorphisms (SNPs) in genes related to PRP and/or their receptors. These SNPs can determine a greater or lesser response to treatment and consequently a shorter or longer recovery time.

In recent years there has been increasing research into genes related to the healing of soft tissue. SNPs in genes that codify for these growth factors could influence treatment effectiveness and explain differences observed in recovery times.

Future studies have to focus on examine the maximum possible number of SNPs in PRP-related genes (or their receptors) in order to identify a gene signature that promotes tissue healing and in order to determine an objective measurement of an individual's predisposition to recovery after this kind of treatment (Table 1).

Nowadays, the use of PRP treatment has increased in a somewhat random manner without real knowledge of its effectiveness, since contradictory results have been reported.

Some growth factors (BMP-2, TGF and FGF) have been proven to enhance the tendon-bone healing process related to ACL injuries, in vitro [14] and graft remodelling and moderation may be accelerated by actions of PDGF, TGF-b1 and IGF-1 [15]. The addition of platelet concentrates to ACL reconstruction may have a beneficial effect on graft maturation and could improve it by 20-30% on average, but with substantial variability, despite there is currently insufficient evidence to support the routine use of PRP for treating ACL injuries [16].

The addition of PRP to a collagen hydrogel resulted in a significant increased cellular metabolic activity, reduced apoptotic rate and stimulation of collagen production in the cells from

Table 1. Best genes linked to PRP or their receptors.

Candidate Growth Factors
Insulin-like growth Factor (IGF-1)
Transforming growth factor b1 (TGFb1)
Endothelail growth factor (EGF)
Fibroblast growth factor (FGF)
Platelet -derived growth factor (PDGF)

the immature and adolescent animals ($p<0.05$) but had less of an effect on adult cells. Maturity may influence the response to PRP [17].

Scientists should provide a tool to identify the individuals and injuries most likely to benefit from PRP treatment and thus improve not only recovery time but also restitutio ad integrum by reducing the risk of re-injury.

Further studies of these SNPs may shed light on the tendency of certain individuals to recover more rapidly and more completely from injuries and may help identify individuals with an enhanced injury repair system.

That is the cornerstone to classify patients within "good or bad responders".

Despite the wide use of PRP injections, research into their clinical efficiency is still in its infancy, and more studies are required to confirm preliminary results and provide stronger scientific evidence [18].

References

1. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. *Sports. Med.* 33, 381-394 (2003).
2. Foster TE, Puskas BL, Mandelbaum BR, *et al.* Platelet-rich plasma: from basic science to clinical applications. *Am. J. Sports. Med.* 37, 2259-2272 (2009).
3. Anitua E, Andia I, Ardanza B, *et al*. Autologous platelet as a source of proteins for healing and tissue regeneration. *Thromb. Haemost.* 91, 4-15 (2004).
4. Kon E, Filardo G, Di Martino A, *et al.* Platelet-rich plasma to treat sports injuries: evidence to support its use. *Knee. Surg. Sports. Traumatol. Arthrosc.* 19, 516-527 (2011).
5. de Vos RJ, van Veldhoven PLJ , Moen MH, *et al.* Autologous growth factor injections in chronic tendinopathy: a systematic review. *British. Med. Bullet.* 1-15 (2010).
6. Mazzocca A, McCarthy R, Chowaniec M*, et al*. (2012) The positive effects of different platelet-rich plasma methods on human muscle, bone and tendon cells. *A. J. Sports. Med.* 40, 1742-1749.
7. de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, *et al*. (2010) Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. *JAMA*. 303, 144-149.
8. Goldman R (2004) Growth factors and chronic wound healing: past, present and future. *Adv. Skin. Wound. Care.* 17, 24-25.
9. Paoloni J, De Vos RJ, Hamilton B*, et al*. (2011) Platelet-rich plasma treatment for ligament and tendon injuries. *Clin. J. Sport. Med.* 21, 37-45.
10. Wetzel RJ, Patel RM, Terry MA. Platelet-rich plasma as an effective treatment for proximal hamstring injuries. *Orthop.* 36: e64-70 (2013).
11. Hamid MS, Mohamed Ali MR, Yusof A, *et al.* Platelet-rich plasma (PRP): an adjuvant to fasten hamstring muscle recovery. A randomized controlled trial protocol (ISCRTN66528592). *BMC Musculo. Disord.* 13, 138 (2012).
12. Bava ED, Barber FA. Platelet-rich plasma products in sports medicine. *Phys. Sportsmed.* 39, 94-99 (2011).
13. Andia I, Sánchez M, Maffulli N. Platelet rich plasma therapies for sports muscle injuries: any evidence behind clinical practice? *Exper. Opin. Biol. Ther.* 11, 509-518 (2011).
14. Hashimoto Y, Yoshida G, Toyoda H, *et al*. Generation of tendon-to-bone interface "enthesis" with use of recombinant BMP-2 in a rabbit model. *J. Orthop. Res*. 25, 1415-1124 (2007).
15. Radice F, Yánez R, Gutiérrez V, *et al.* Comparison of resonance imaging findings in ACL grafts with and without autologous platelet- derived growth factors. *Arthro.* 26, 50-57 (2010).
16. Moraes VY, Lenza M, Tamaoki MJ, et al. Platelet-rich therapies for musculoskeletal soft tissue injuries. *Cochrane. Database. Syst. Rev.* 23(12), 10071 (2013).
17. Shi S, Mercer S, Eckert GJ, *et al.* (2012) Regulation of articular chondrocyte aggrecan and collagen gene expression by multiple growth factor genetransfer. *J. Orthop. Res.* 30, 1026-1031.
18. Pruna R, Til L, Artells R. Could single nucleotide polymorphisms influence on the efficacy of platelet-rich plasma in the treatment of sport injuries? *Mus. Ligaments. Tendons. J.* 4, 63-65 (2014).